Posted by Michael Wonder on 07 Oct 2024
Crossing the equity chasm: addressing a second valley of death in biomedical innovation
3 October 2024 - Traditionally, the term valley of death refers to the gap where advancements in basic research fail to achieve clinical translation.
Progression from discovery science to marketable technology is fraught with risks, including uncertainties in operationalisation, efficacy, and market demand.
Today, the valley of death for drug development involves a 15 to 20 year timeline, a price of $1 billion to $2 billion, and a 95% failure rate.
